93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Titel:
93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Auteur:
Lu, Y-S. El Saghir, N.S. Hurvitz, S.A. Tripathy, D. Cardoso, F. Colleoni, M.A. Campos-Gomez, S. Franke, F.A. Oregan, R. Wang, C. Wang, Y. Zarate, J.P. Chakravartty, A. Im, S-A.